Search

Sartorius Stedim Biotech.

Închisă

SectorFinanțe

173.85 -3.66

Rezumat

Modificarea prețului

24h

Curent

Minim

172.5

Maxim

182.9

Indicatori cheie

By Trading Economics

Venit

15M

41M

Vânzări

96M

751M

P/E

Medie Sector

101.306

22.015

EPS

1.03

Randament dividend

0.37

Marjă de profit

5.444

Angajați

9,901

EBITDA

-17M

133M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+27.15% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.37%

3.90%

Următoarele câștiguri

16 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.5B

18B

Deschiderea anterioară

177.51

Închiderea anterioară

173.85

Sentimentul știrilor

By Acuity

16%

84%

32 / 542 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Sartorius Stedim Biotech. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 apr. 2025, 23:55 UTC

Acțiuni populare

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr. 2025, 22:50 UTC

Principalele dinamici ale pieței

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr. 2025, 21:08 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr. 2025, 21:00 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr. 2025, 23:44 UTC

Top știri

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr. 2025, 22:43 UTC

Top știri
Achiziții, Fuziuni, Preluări

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr. 2025, 21:48 UTC

Top știri

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr. 2025, 21:04 UTC

Top știri

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr. 2025, 20:53 UTC

Câștiguri

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr. 2025, 20:52 UTC

Câștiguri

Kaiser Aluminum Changes Inventory Acctg Methodology

Sartorius Stedim Biotech. Așteptări

Obiectiv de preț

By TipRanks

27.15% sus

Prognoză pe 12 luni

Medie 230.33 EUR  27.15%

Maxim 269 EUR

Minim 155 EUR

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSartorius Stedim Biotech. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

6

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 181.4Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

32 / 542 Clasament în Finanțe

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.